| abstract |
Pharmaceutical compositions comprising pyrimidin-5-yl- (3R, 5S) -3,5-dihydroxyhept-6-enoic acid or a salt thereof, its stabilization with tribasic phosphate salt and its preparation. In addition to the mentioned acid or its salt, these compositions contain a tribasic phosphate salt of multivalent cation and other ingredients necessary for its proper administration, the phosphate salt acting as a stabilizing agent. The final pharmaceutical compositions are prepared by incorporating the phosphate salt in a starting pharmaceutical composition containing said acid or its salt. The compositions remain stable for a long time and have an HMG CoA reductase inhibitory effect. |